(SWX:SANN), Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE(R) (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Dario Eklund, Chief Executive Officer of Santhera, […]

(SWX:ASCN), Ad hoc announcement pursuant to Art. 53 LRBaar (Switzerland), 15 January 2026 Based on preliminary unaudited figures, Ascom reports for fiscal year 2025 net revenue of CHF 292.1 million, which is an increase of around 3.8% at constant currencies, and an EBITDA margin of around 11.5% to 12.0%. Ascom generated net revenue of CHF

Santhera Receives Swissmedic Approval of AGAMREE(R) (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire January 15, 2026 Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE(R) (vamorolone) for the treatment of Duchenne muscular

Ascom preliminary results 2025 GlobeNewswire January 15, 2026 Ad hoc announcement pursuant to Art. 53 LRBaar (Switzerland), 15 January 2026 Based on preliminary unaudited figures, Ascom reports for fiscal year 2025 net revenue of CHF 292.1 million, which is an increase of around 3.8% at constant currencies, and an EBITDA margin of around 11.5% to

Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market GlobeNewswire January 15, 2026 LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) — Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially

Press Release: Myqorzo and Redemplo approved in China GlobeNewswire January 15, 2026 Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs Paris,

(Strategic Expansion Positions YI TING as Resilient Supply Partner, Cutting Lead Times By Up to 30% for Sustainable Filtration) Trusted by world-renowned specialty coffee equipment innovators and Tier-1 roasters, YI TING Non-Woven, a leading Taiwanese manufacturer of engineered nonwoven materials, today announced a major capacity doubling to scale support for its rapidly growing client base

A news report from Haikou Municipal Bureau of Tourism, Culture, Radio, Television and Sports: Recently, the “Haikou on Stage, Dancing with the World” International Performing Arts Capital Promotion Conference was successfully held in Haikou. Centered on the theme “Culture Empowering Cities, Art Illuminating the Future,” the event combined immersive audiovisual experiences with in-depth industry dialogue,

GEORGE TOWN, Cayman Islands, Jan. 15, 2026 (GLOBE NEWSWIRE) — Toobit, the award-winning global cryptocurrency exchange, today announces the release of its 2025 Recap. This personalized year-in-review offers a comprehensive analysis of individual milestones alongside actionable tips for the year ahead. Whether celebrated as a “Master Strategist” or recognized as a “Patient Observer,” every Toobit

Toobit Unveils 2025 Recap, a Personalized Year-in-Review for Traders GlobeNewswire January 15, 2026 GEORGE TOWN, Cayman Islands, Jan. 15, 2026 (GLOBE NEWSWIRE) — Toobit, the award-winning global cryptocurrency exchange, today announces the release of its 2025 Recap. This personalized year-in-review offers a comprehensive analysis of individual milestones alongside actionable tips for the year ahead. Whether